Previous 10 | Next 10 |
Investment Thesis Alexion Pharmaceuticals, Inc. ( ALXN ) is yet to recover from the last year's patent challenges to the leading revenue generator, Soliris. Over the past twelve months, the stock has lost more than a fifth while the Nasdaq Biotechnology Index has gained nearly a tenth. See...
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the U.S. Food and Drug Administration’s (FDA) clearance of the Investigational New Drug (IND) application for the HEALEY ALS Platform Trial for the treatment of amyotrophic lateral sclerosis (ALS). Zilucoplan was selected as one of...
Merger activity increased, with nine new deals announced and six deals closing. Deal Statistics New Deals The acquisition of LogMeIn (LOGM) by Francisco Partners for $4.3 billion or $86.05 per share in cash. We added LOGM as a potential deal to the Deals in the Works section on Dece...
Topline data from an initial six-subject cohort in an open-label, single-arm Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...
Top-line results expected in the second half of 2020 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). “IMNM is a chronic, severe, and ...
NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related t...
NEW YORK, NY / ACCESSWIRE / November 21, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . ( NASDAQ: RARX ) re...
CdbMD (NYSEMKT: YCBD ) initiated with Neutral rating and $3.40 (15% downside risk) price target at Cantor Fitzgerald. More news on: cbdMD, Inc., CV Sciences, Inc., Portola Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Ra Pharmaceuticals (NASDAQ: RARX ): Q3 GAAP EPS of -$0.55 misses by $0.05 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...